Newblue-CHEM - Nir...

Newblue-CHEM - Niraparib

Newblue-CHEM - Niraparib

Min.Order / FOB Price:Get Latest Price

1 Gram

FOB Price: USD 1000.0000

  • Min.Order :1 Gram
  • Purity: 99.0%
  • Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Niraparib 1038915-60-4 C19H20N4O

Quick Details

  • Appearance:Solid
  • Application:Organic synthesis
  • PackAge:IN 25kg drums
  • ProductionCapacity:10|Metric Ton|Month
  • Storage:In Room Temperature
  • Transportation:As per MSDS

Superiority:

Henan Newblue Chemical Co., Ltd. is located in Zhengzhou High-tech Development Zone with import and export license.

We passed ISO 9001:2008 in 2009, and won "High-tech Enterprise" by provincial government in 2013.The objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal.

Improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. We are constantly striving to make Henan Newblue a leading chemical supplier, and hope to create a better future with you.

Details:

Niraparib Basic information
Product Name: Niraparib
Synonyms: (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827,(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxaMide;Niraparib;2-[4-((3S)-3-Piperidinyl)phenyl]-2H-indazole-7-carboxamide;MK4827 (Niraparib);2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-;(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide hydrocholoride;Niraparib (MK-4827)
CAS: 1038915-60-4
MF: C19H20N4O
MW: 320.3883
EINECS:
Product Categories: API;Anti-cancer&immunity
Mol File: 1038915-60-4.mol
Niraparib Structure
Niraparib Chemical Properties
density 1.34
Safety Information
MSDS Information
Niraparib Usage And Synthesis
Description (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide is also known as MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 (The poly(ADP-ribose) polymerase) with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It has been recently approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death.
References #
#
#
Sandhu, Shahneen K, et al. "The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA, mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial." Lancet Oncology14.9 (2013):882.
Jones, P, et al. "Niraparib: A Poly (ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. " Journal of Medicinal Chemistry 58.8(2015):3302-14.
Niraparib Preparation Products And Raw materials

 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View